Treatment Pathway

Treatment of Overactive Bladder

Overactive bladder is characterized by urinary urgency with or without urge incontinence, increased daytime frequency, and nocturia. It affects up to 16% of adults.

KDIGO (Kidney Disease Improving Global Outcomes)ERA (European Renal Association)AUA (American Urological Association)NICEEAU (Urological)

Symptoms Causes Treatment When to See a Doctor Related Questions

Overactive bladder is characterized by urinary urgency with or without urge incontinence, increased daytime frequency, and nocturia. It affects up to 16% of adults.

First-Line Treatment Principles

✓BP control: target <130/80 mmHg; ACE inhibitor or ARB for proteinuric CKD
✓SGLT2 inhibitors for CKD with proteinuria (regardless of diabetes): reduce CKD progression by 30–40%
✓Treat underlying cause: immunosuppression for glomerulonephritis, antiviral for viral-associated nephropathy
✓Fluid management: adequate hydration in AKI; fluid restriction in oliguric/ESRD patients
✓Treat complications: anaemia (EPO/iron), bone disease (phosphate binders, vitamin D), hyperkalaemia

Medications Used in Overactive Bladder

OxybutyninAnticholinergic

Oxybutynin is an anticholinergic or beta-3 agonist used to treat overactive bladder by reducing urinary urgency and frequency.

SolifenacinAnticholinergic

Solifenacin is an anticholinergic or beta-3 agonist used to treat overactive bladder by reducing urinary urgency and frequency.

MirabegronAnticholinergic

Mirabegron is an anticholinergic or beta-3 agonist used to treat overactive bladder by reducing urinary urgency and frequency.

Non-Pharmacological Management

•Dietary protein restriction (0.6–0.8 g/kg/day) in advanced CKD to slow progression
•Sodium restriction (<2g/day) for BP and fluid management
•Potassium restriction in hyperkalaemia; phosphate restriction in ESRD
•Fluid management: adequate intake in early CKD; restrict to 1.0–1.5L/day in oliguric ESRD
•Smoking cessation: accelerates CKD progression
•Weight management: obesity drives glomerular hyperfiltration and proteinuria
•Regular aerobic exercise where tolerated; renal rehabilitation programmes

Treatment Goals

🎯Slow CKD progression: halve rate of GFR decline; delay dialysis/transplant

🎯UACR <30 mg/mmol (or >50% reduction from baseline)

🎯BP <130/80 mmHg; haemoglobin 100–120 g/L

🎯Preserve quality of life; minimise uraemic symptoms

🎯Renal replacement therapy (dialysis or transplant) when eGFR <10–15 and uraemic symptoms present

Monitoring Parameters

◆eGFR and creatinine: 3–6 monthly in CKD stages 3–4; monthly in CKD stage 5 or rapid progressors
◆Urine albumin-creatinine ratio (UACR): every 3–6 months
◆Electrolytes: potassium (ACE inhibitor/ARB risk), sodium, bicarbonate, phosphate — 3–6 monthly
◆FBC: haemoglobin target 100–120 g/L with EPO therapy
◆Parathyroid hormone (PTH), calcium, phosphate: for renal bone disease monitoring
◆BP: target at every visit

Escalation Criteria

→AKI: urgent assessment for reversible causes; IV fluids if pre-renal; emergency dialysis if urea >35, K+>6.5, acidosis, or fluid overload
→Rapidly progressive GFR decline → renal biopsy and specialist nephrology review
→Hyperkalaemia >6.5 mmol/L: immediate cardiac monitoring, calcium gluconate IV, insulin-dextrose, dialysis if refractory
→Prepare for renal replacement therapy (RRT) education when eGFR <20: home dialysis or transplant listing

Special Populations

Elderly: reduced renal reserve; drug dosing adjustment essential; less aggressive BP targets to avoid AKI

Diabetes: combination of ACE inhibitor + SGLT2i provides maximal nephroprotection

Pregnancy: pre-existing CKD significantly increases maternal and fetal risks; specialist obstetric nephrology essential

Transplant recipients: immunosuppression (calcineurin inhibitors, steroids, MMF); vigilance for opportunistic infections

Clinical Insights

Differential Diagnosis

Conditions that mimic Overactive Bladder — key distinguishing features & tests

Not sure about your symptoms?

Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.

Use AI Symptom Checker →